Medication
Taro-Docusate
DIN 00716731 · Taro Pharmaceuticals Inc Likely a generic
What it is
- Active ingredients
- Docusate Sodium — 100 mg
- Form and route
- Capsule · Oral
- Schedule
- NON-PRESCRIPTION DRUGS
- Authorised since
- 1988-12-31
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
- Selax Cap 100MG
- PMS-Docusate Sodium
- Soflax Capsules 100MG
- Colace Capsules
- Stool Softener
- Stool Softener
- Stool Softener
- Docusate Sodium
- M-Docusate Sodium 100 MG
- Colace Clear
- Nra-Docusate Sodium
- Stool Softener Clear
Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.
Watch this medication
Ontario Drug Benefit coverage
As of 31 July 2026General benefit Part III-A
Ontario lists this product as a general benefit under the Ontario Drug Benefit program — Part III-A of the Formulary/CDI. For someone eligible for ODB, it is covered without a drug-specific approval.
- What ODB pays per unit
- $0.0328
This is what the Ontario Drug Benefit program reimburses a pharmacy for one unit, as of 31 July 2026. A deductible and a co-payment sit on top of it and differ by program — ODB, the Trillium Drug Program and the seniors co-payment each work differently — so it is not the figure anyone is charged at a counter. It also says nothing about private, workplace or federal coverage.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
Products Ontario considers interchangeable
As of 31 July 2026Ontario groups these products together at 100mg Cap and will substitute one for another at a pharmacy counter in Ontario.
- Colace Capsules 02106256Pharmascience Inc
- Soflax Capsules 100MG 01994344Pharmascience Inc
Ontario lists 1 further product in this group that is not currently marketed in Canada. It is not shown.
This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Alimentary tract and metabolism
- ATC code
- A06AA02
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of A06AA02, see the WHO ATC/DDD Index.
Recalls and safety alerts
As of 12 August 2026Archived by Health Canada
1 older notice naming this product has been archived. These are a record of what happened, not current warnings.
Taro-Docusate Capsules USP 100 mg (2014-04-25)
Matched on the product name at the start of the notice.
This list may be incomplete. Health Canada’s recalls data carries no DIN, so notices are matched on wording alone. Search Health Canada recalls for Taro-Docusate → How RxMonitor matches recalls, and how often it fails
Source: Health Canada — Recalls and Safety Alerts. Data current as of 2026-08-12. Matched on product name, not on DIN — the feed carries none.